Bretaris

Bretaris Uses, Dosage, Side Effects, Food Interaction and all others data.

Bretaris is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

Bretaris does not prolong the QTc interval or have significant effects on cardiac rhythm.

Trade Name Bretaris
Availability Prescription only
Generic Aclidinium
Aclidinium Other Names Aclidinio
Related Drugs Trelegy Ellipta, ProAir Digihaler, prednisone, Symbicort, Breo Ellipta, Ventolin, Xopenex, Ventolin HFA, Spiriva, Anoro Ellipta
Type
Formula C26H30NO4S2
Weight Average: 484.651
Monoisotopic: 484.161624833
Groups Approved
Therapeutic Class
Manufacturer
Available Country Austria, Croatia (Hrvatska), Germany, Hungary, Lithuania, Poland, Slovakia, Slovenia, Spain
Last Updated: September 19, 2023 at 7:00 am
Bretaris
Bretaris

Uses

Bretaris is an inhaled long-acting anticholinergic used as a maintenance bronchodilator in patients with chronic obstructive pulmonary disease (COPD).

Bretaris bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Bretaris is also used to associated treatment for these conditions: Chronic Obstructive Pulmonary Disease (COPD)

How Bretaris works

Bretaris is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Bretaris's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.

Toxicity

Most common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.

Food Interaction

No interactions found.

Volume of Distribution

Following IV administration, the volume of distribution is 300 L

Elimination Route

Bioavailability, healthy subjects = 6%; T max, healthy subjects = 10 minutes; Time to steady state, healthy subjects = 2 days;

Half Life

Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). Effective half-life = 5-8 hours.

Clearance

Total clearance, IV dose, young healthy subjects = 170 L/h (inter-individual variability of 36%)

Elimination Route

Intravenously administered radiolabelled aclidinium bromide was administered to healthy volunteers and was extensively metabolized with 1% excreted as unchanged aclidinium. Approximately 54% to 65% of the radioactivity was excreted in urine and 20% to 33% of the dose was excreted in feces. The combined results indicated that almost the entire aclidinium bromide dose was eliminated by hydrolysis. After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose.

Innovators Monograph

You find simplified version here Bretaris

*** Taking medicines without doctor's advice can cause long-term problems.
Share